Recent Articles

March 18, 2015 9:11 am
Daniel N. Galbraith, Ph.D., BioOutsource Ltd
In the past 10 years biosimilars have held strong in the biologics industry’s headlines. These products were once thought impossible to approve in regulated markets because the sheer complexity of producing these large, complex proteins can result in “robustness” issues. Read more...
March 16, 2015 3:58 pm
Cynthia Fox, Science Editor
A clinical trial of the most common sickle cell anemia drug, hydroxyurea, was halted a year early this winter because of “overwhelming evidence of benefit,” reported University of Nebraska Medical Center pediatric researcher Stephen Obaro, M.D., Ph.D., in The Lancet. Read more...
March 12, 2015 8:45 am
Eliseo Salinas, MD, MSc, President and Chief Scientific Officer, Relmada Therapeutics
At a time when opioid abuse and addiction are making headlines, a new molecule is being studied to treat neuropathic pain without such negative effects. Read more...                        
March 11, 2015 2:34 pm
Ryan Bushey, Associate Editor
Endo is trying to upset the agreement Valeant Pharmaceuticals made last month to buy Salix. Read more...                          
March 11, 2015 10:13 am
Ryan Bushey, Associate Editor
Stanford is one of the institutions Apple teamed up with to launch this program. Read more...                           
March 11, 2015 8:57 am
Bevin Fletcher, Associate Editor, Bioscience Technology
Getting a new drug to market is difficult, but the U.S. Food and Drug Administration (FDA) offers a number of ways to help the process along for promising drugs that have potential against serious diseases. Read more...
March 10, 2015 11:59 am
Stephanie Guzowski, Editor
The U.S. Food and Drug Administration (FDA) has determined it will not reduce the severity of its black-box warning about side effects associated with Pfizer’s smoking-cessation drug. Read more...                                                
March 10, 2015 11:52 am
Ryan Bushey, Associate Editor
Technology has made it very hard to crush or melt this drug. Read more...                               
March 6, 2015 3:18 pm
Ryan Bushey, Associate Editor
Investors did not seem pleased about this deal. Read more...
March 5, 2015 11:50 am
Ryan Bushey, Associate Editor
The startup has been called "The Yelp of Medicine." Read more...                                                         
Subscribe to Drug Discovery & Development